Drugs / Dendritic Cell Tumor Cell Lysate Vaccine
Dendritic Cell Tumor Cell Lysate Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04201873 | Jan 2020 → Aug 2026 overdue | glioblastoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell Tumor Cell Lysate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04201873 ↗ |
| Known as | ATL-DC | “autologous tumor lysatepulsed dendritic cell (ATL-DC) vaccination” NCT04201873 ↗ |
| Known as | ATL-DC vaccine | “a vaccine therapy (ATL-DC vaccine)” NCT04201873 ↗ |
| Modality | Vaccine | “a vaccine therapy (ATL-DC vaccine)” NCT04201873 ↗ |